Myasthenia gravis with myasthenic crisis: a case report

Main Article Content

Fernando Cotrim Gomes
Paulo Roberto Nolli Filho
Gabriel Anselmo Frota
Geanne Muniz Meira
Fernando Lucas Santos
Lyster Dabien Haddad
Luís Felipe José Ravic de Miranda

Abstract

Objective: To present a favorable outcome in a Myasthenia gravis (MG) patient with myasthenic crisis and discuss its main diagnostic challenges. Case detail: We report the case of a previously healthy 80-year-old male who first presented with dysphagia that quickly progressed to a generalized myasthenic syndrome leading to ICU admission and intubation over the course of less than two months. He was investigated firstly for thymoma, followed by Parkinson’s disease and Lambert-Eaton syndrome before closing on MG. He was successfully stabilized after a month-long ICU stay intercurring with multiple infections and respiratory failure. Currently presenting no sequalae or recurrence. Final considerations: Myasthenia gravis is an important autoimmune neuromuscular disorder that affects the neuromuscular junction. It has many possible signs and symptoms, depending on the most affected muscle group. Although there is no cure for it, an early diagnosis allows an approach and treatment that provides a better quality of life, and the prevention of related complications. We discuss how to assess the main differential diagnoses, including Parkinson’s disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Lambert-Eaton Syndrome, and others, to help clinicians facing a similar patient and avoid a poor outcome on a fast-paced progression case such as the one we report.

Article Details

How to Cite
GomesF. C., Nolli FilhoP. R., FrotaG. A., MeiraG. M., SantosF. L., HaddadL. D., & MirandaL. F. J. R. de. (2023). Myasthenia gravis with myasthenic crisis: a case report. Electronic Journal Collection Health, 23(9), e13435. https://doi.org/10.25248/reas.e13435.2023
Section
Estudos de Caso

References

1. ADELMAN HM, et al. D-penicillamine-induced myasthenia gravis: diagnosis obscured by coexisting chronic obstructive pulmonary disease. Am J Med Sci. 1995; 309(4): 191-3.

2. BEITZ JM. Parkinson's disease: a review. Front Biosci (Schol Ed). 2014; 6(1): 65-74.

3. CARRILLO-MARQUEZ MA. Botulism. Pediatr Rev. 2016; 37(5): 183-92.

4. DEHBASHI S et al. Co-occurrence of multiple sclerosis and myasthenia gravis: A case report and review of immunological theories. Mult Scler Relat Disord. 2019; 34: 135-136.

5. DOBSON R, GIOVANNONI G. Multiple sclerosis - a review. Eur J Neurol. 2019; 26(1): 27-40.

6. GARCIA-GARCIA J et al. A series of patients with refractory myasthenia gravis. Neurologia (Engl Ed). 2020: S0213-4853(20): 30293-0.

7. GILHUS NE et al. Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016; 12(5): 259-68.

8. GILHUS NE, VERSCHUUREN JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015; 14(10): 1023-36.

9. GILHUS NE. Myasthenia Gravis. New England Journal of Medicine. 2016; 375(26): 2570-2581.

10. GROVER S et al. Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease: Evidence From the COURAGE-PD Consortium. Neurology. 2022; 16; 99(7).

11. HA JC, RICHMAN DP. Myasthenia gravis and related disorders: Pathology and molecular pathogenesis. Biochim Biophys Acta. 2015; 1852(4): 651-7.

12. HEHIR MK, SILVESTRI NJ. Generalized Myasthenia Gravis. Neurologic Clinics. 2018; 36(2): 253-260.

13. HERNANDEZ FUSTES OJ et al. Myasthenia Gravis with Elderly Onset at Advanced Age. Cureus. 2020; 12(1): 29.

14. MICHAEL KEOGH, et al. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database of Systemic Reviews. 2021; 2: 1465-58.

15. NA ZHANG, et al. 3,4-diaminopyeidine treatment for Lambert Eatonmyasthenic syndrome in adults: a meta-analysis of randomized controlled trials. BMC Neurology. 2021; 21(1): 371.

16. PASCUZZI RM and BODKIN CL. Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome: New developments in diagnosis and treatment. Neuropsychiatr Dis Treat. 2022; 18: 3001-3022.

17. POSTUMA RB et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015; 30(12): 1591-1601.

18. POZZILLI C et al. Diagnosis and treatment of progressive multiple sclerosis: A position paper. Eur J Neurol. 2023; 30(1): 9-21.

19. SHEIKH S et al. Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update. J Clin Med. 2021 6; 10(7): 1537.

20. SINGH N et al. Clinical Mimickers of Amyotrophic Lateral Sclerosis-Conditions We Cannot Afford to Miss. Ann Indian Acad Neurol. 2018; 21(3): 173-178.

21. THANVI, B R. Update on myasthenia gravis. Postgraduate Medical Journal. 2004; 80(950): 690-700.

22. VINCENT A et al. Serological and experimental studies in different forms of myasthenia gravis. Ann N Y Acad Sci. 2018; 1413(1): 143-153.

23. WIRTZ PW et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2002; 73(6): 766-8.